RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model

This study evaluated the clinical activity of RGN-259 (thymosin β4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. The model was NOD.B10-H2(b) mice in a 30–40% humidified environment together with daily scopolamine hydrobromide injectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chae Eun, Kleinman, Hynda K., Sosne, Gabriel, Ousler, George W, Kim, Kyeongsoon, Kang, Sinwook, Yang, Jaewook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043477/
https://www.ncbi.nlm.nih.gov/pubmed/30002412
http://dx.doi.org/10.1038/s41598-018-28861-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043477/
https://www.ncbi.nlm.nih.gov/pubmed/30002412
http://dx.doi.org/10.1038/s41598-018-28861-5

Ejemplares similares